Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 23444

Negotiation Status:

Active Negotiation

Indication(s):

For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0420-000

pCPA Engagement Letter Issued:

2026-01-09

Negotiation Process Concluded:

Not Applicable